guest ::
| Home > Publications Database > TMEM106B modulates disease severity in genetic frontotemporal dementia phenoconverters > print |
| Home > Publications Database > TMEM106B modulates disease severity in genetic frontotemporal dementia phenoconverters > print |
| 001 | 283071 | ||
| 005 | 20251230103620.0 | ||
| 024 | 7 | _ | |a 10.1002/alz70856_103532 |2 doi |
| 024 | 7 | _ | |a pmid:41449512 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12741048 |2 pmc |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 037 | _ | _ | |a DZNE-2025-01478 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pasternak, Maurice |b 0 |
| 111 | 2 | _ | |a Alzheimer’s Association International Conference |g AAIC 25 |c Toronto |d 2025-07-27 - 2025-07-31 |w Canada |
| 245 | _ | _ | |a TMEM106B modulates disease severity in genetic frontotemporal dementia phenoconverters |
| 260 | _ | _ | |c 2025 |
| 336 | 7 | _ | |a Abstract |b abstract |m abstract |0 PUB:(DE-HGF)1 |s 1767011723_31206 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |m journal |
| 336 | 7 | _ | |a Output Types/Conference Abstract |2 DataCite |
| 336 | 7 | _ | |a OTHER |2 ORCID |
| 520 | _ | _ | |a A common variant within TMEM106B is associated with risk for Frontotemporal Lobar Degeneration-Tar DNA binding Protein-43 (FTLD-TDP). A recent study has shown that the minor allele G of TMEM106B-rs1990622 confers protection against FTLD-TDP in symptomatic mutation carriers through reductions in NfL serum levels, brain atrophy, and cognitive decline. It is unknown whether this protective effect is present in phenoconverters of the disease.We included 518 participants from the GENetic Frontotemporal dementia Initiative (GENFI), which recruits genetic FTD cases and their family members, both carriers and non-carriers of FTD mutations. Of these, 21 were phenoconverters, 209 were non-carrier controls, 70 were presymptomatic and 45 symptomatic C9orf72 carriers, 92 presymptomatic and 29 symptomatic GRN carriers, and 39 presymptomatic and 13 symptomatic MAPT carriers. Effects of interaction between TMEM106B-rs1990622 and phenoconverter status were examined using mixed effects models, with a random effects structure featuring subjects nested within families and fixed effects for age at baseline and sex. Serum neurofilament light chain (NfL) was measured using the Simoa platform. Cognitive assessment included the Mini-Mental State Examination (MMSE), tests of attention, processing speed, executive function, and language, as well as the Cambridge Behavioural Inventory (CBI), with mixed effects also including years of education as a covariate. Brain volumetry was assessed using T1-weighted MRI and these mixed effect models also included additional covariates of total intracranial volume and scanner site.In phenoconverters, each copy of the protective allele G was associated with a significant reduction in the rate of serum NfL accumulation (-5.33 pg/mL/year; p = 7.79 × 10-9). Structural imaging analyses revealed decreased rates of atrophy in fronto-orbital regions and the insular cortex among protective allele carriers. Cognitive trajectories showed significantly slower decline across multiple domains including general cognition (MMSE; p = 0.003), attention and processing speed (p = 2.2 × 10-4), executive function (p = 2.6 × 10-7), language (p = 2.9 × 10-3), and behavioural symptoms as measured by CBI (p = 9.5 × 10-3).The TMEM106B-rs1990622 protective variant significantly modulates disease progression in genetic FTD phenoconverters across multiple markers, suggesting its potential as a therapeutic target. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Nerve Tissue Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers |2 NLM Chemicals |
| 650 | _ | 7 | |a TMEM106B protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Membrane Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a C9orf72 Protein |2 NLM Chemicals |
| 650 | _ | 7 | |a tau Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Progranulins |2 NLM Chemicals |
| 650 | _ | 7 | |a Neurofilament Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a C9orf72 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a MAPT protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a neurofilament protein L |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Nerve Tissue Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Biomarkers: blood |2 MeSH |
| 650 | _ | 2 | |a Membrane Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Frontotemporal Dementia: genetics |2 MeSH |
| 650 | _ | 2 | |a Frontotemporal Dementia: pathology |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a C9orf72 Protein: genetics |2 MeSH |
| 650 | _ | 2 | |a Brain: pathology |2 MeSH |
| 650 | _ | 2 | |a Brain: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a tau Proteins: genetics |2 MeSH |
| 650 | _ | 2 | |a Progranulins: genetics |2 MeSH |
| 650 | _ | 2 | |a Neurofilament Proteins: blood |2 MeSH |
| 650 | _ | 2 | |a Mutation: genetics |2 MeSH |
| 650 | _ | 2 | |a Magnetic Resonance Imaging |2 MeSH |
| 650 | _ | 2 | |a Atrophy |2 MeSH |
| 700 | 1 | _ | |a Mirza, Saira S |b 1 |
| 700 | 1 | _ | |a Paterson, Andrew D |b 2 |
| 700 | 1 | _ | |a Tartaglia, Carmela |b 3 |
| 700 | 1 | _ | |a Mitchell, Sara |b 4 |
| 700 | 1 | _ | |a Black, Sandra E |b 5 |
| 700 | 1 | _ | |a Freedman, Morris |b 6 |
| 700 | 1 | _ | |a Tang-Wai, David F |b 7 |
| 700 | 1 | _ | |a Rogaeva, Ekaterina |b 8 |
| 700 | 1 | _ | |a Cash, David M |b 9 |
| 700 | 1 | _ | |a Bocchetta, Martina |b 10 |
| 700 | 1 | _ | |a van Swieten, John |b 11 |
| 700 | 1 | _ | |a Laforce, Robert |b 12 |
| 700 | 1 | _ | |a Tagliavini, Fabrizio |b 13 |
| 700 | 1 | _ | |a Borroni, Barbara |b 14 |
| 700 | 1 | _ | |a Galimberti, Daniela |b 15 |
| 700 | 1 | _ | |a Rowe, James B |b 16 |
| 700 | 1 | _ | |a Graff, Caroline |b 17 |
| 700 | 1 | _ | |a Finger, Elizabeth |b 18 |
| 700 | 1 | _ | |a Sorbi, Sandro |b 19 |
| 700 | 1 | _ | |a de Mendonça, Alexandre |b 20 |
| 700 | 1 | _ | |a Butler, Christopher |b 21 |
| 700 | 1 | _ | |a Gerhard, Alexander |b 22 |
| 700 | 1 | _ | |a Sánchez-Valle, Raquel |b 23 |
| 700 | 1 | _ | |a Moreno, Fermin |b 24 |
| 700 | 1 | _ | |a Synofzik, Matthis |0 P:(DE-2719)2811275 |b 25 |u dzne |
| 700 | 1 | _ | |a Vandenberghe, Rik |b 26 |
| 700 | 1 | _ | |a Ducharme, Simon |b 27 |
| 700 | 1 | _ | |a Levin, Johannes |0 P:(DE-2719)2811659 |b 28 |u dzne |
| 700 | 1 | _ | |a Otto, Markus |b 29 |
| 700 | 1 | _ | |a Santana, Isabel |b 30 |
| 700 | 1 | _ | |a Rohrer, Jonathan D |b 31 |
| 700 | 1 | _ | |a Masellis, Mario |b 32 |
| 700 | 1 | _ | |a GENFI |b 33 |e Collaboration Author |
| 773 | _ | _ | |a 10.1002/alz70856_103532 |g Vol. 21 Suppl 2, no. Suppl 2, p. e103532 |0 PERI:(DE-600)2201940-6 |n Suppl 2 |p e103532 |t Alzheimer's and dementia |v 21 Suppl 2 |y 2025 |x 1552-5260 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/283071/files/DZNE-2025-1478.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/283071/files/DZNE-2025-1478.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:283071 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 25 |6 P:(DE-2719)2811275 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 28 |6 P:(DE-2719)2811659 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2025-01-06 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1111015 |k Clinical Research (Munich) |l Clinical Research (Munich) |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1111016 |k AG Levin |l Clinical Neurodegeneration |x 2 |
| 980 | _ | _ | |a abstract |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)1111015 |
| 980 | _ | _ | |a I:(DE-2719)1111016 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|